Objectives: The aim of this study was to prospectively survey transmitted drug resistance (TDR) among recently infected individuals (mostly MSM).
Introduction
The HIV epidemic in Thailand started in 1985 among MSM, 1 then expanded to include intravenous drug users and sequentially spread to female sex workers, their male clients and then heterosexual women and newborns. 2 Though overall HIV incidence in Thailand is decreasing, prevalence and incidence among MSM are increasing. 3 In developing countries where HIV drug resistance (HIVDR) testing prior to ART is not generally available due to cost and infrastructure constraints, the prospective surveillance of transmitted drug resistance (TDR) among recently infected individuals can inform policies regarding first-line ART regimens and the cost-effectiveness of HIVDR testing. A meta-regression analysis by the WHO of TDR trends in developing countries showed that TDR, especially to NNRTIs, increased significantly after ART rollout (2001 -11) in sub-Saharan Africa to as high as 7.4% (4.3% -12.7%). Less evidence to support determination of trends exists in Asia. 4 Low prevalence (,5%) of TDR was reported among individuals recently infected with HIV in Bangkok in 2005 -06 5 using WHO threshold surveillance methods. However, increasing HIV prevalence among MSM suggests this as an appropriate target group for continued TDR surveillance. Here, we report findings from a prospective, annual TDR survey in recently infected, treatmentnaive individuals at the Anonymous Clinic of the Thai Red Cross AIDS Research Centre (TRC-ARC) in Bangkok, Thailand during 2008-10.
Methods

Study population
As part of a regional multicentre study on HIVDR in Asia (TREAT Asia Studies to Evaluate Resistance-Surveillance), 80 recently HIV-1-infected, antiretroviral-naive individuals were consecutively recruited each year from 2008 to 2010 at the TRC-ARC. Only newly infected MSM were consecutively Determination of TDR and drug susceptibility HIVDR testing was done with an in-house assay covering amino acids 1 -99 of the protease (Pr) gene and amino acids 20-260 of the reverse transcriptase (RT) gene. TDR was defined by the presence of at least one amino acid mutation as listed in the 2009 WHO surveillance drug resistance mutation (SDRM) list. 6 Predicted susceptibility scores to specific antiretroviral drugs were estimated using the Stanford HIV Sequence Database drug susceptibility tool (version 7.0, sierra2.stanford.edu/sierra/servlet/ JSierra, calculated on 6 September 2014). These scores were used to classify participants into three resistance levels per drug: low-(,30), intermediate-(30 -59) and high-level (≥60) resistance, respectively. The WHO's cost-saving method of determining TDR prevalence in small sample sizes 7 was tested in our larger sample set in order to evaluate its compatibility. The WHO method as well as the methods of HIV testing, HIV subtyping, Stanford drug susceptibility scoring, data collection and statistical methods used are described in the Supplementary data (available at JAC Online).
Results
Demographic and laboratory characteristics
A total of 299 recently infected subjects with a mean age of 23 years were consecutively enrolled from 2008 (n ¼ 130), 2009 (n ¼ 89) and 2010 (n ¼ 80). Among these, 264 (88%) were MSM and 34 (11%) were heterosexuals (Table 1) . Median viral load (VL) in 2008 was significantly lower than in 2010 among MSM (P ¼ 0.006) as well as among all subjects (P ¼ 0.004). There were no significant differences in age, CD4 and VL between the 29 non-MSM and 101 MSM enrolled in 2008.
Genotypic drug resistance
Of the 299 enrolled subjects, 284 RT/Pr sequences were analysable (124 from 2008, 84 from 2009 and 76 from 2010): 5 were only amplifiable in either RT or Pr and 10 were not amplifiable, all with VLs between 39 and 1200 copies/mL.
Fourteen of 284 sequences (4.9%, 95% CI 2.8% -8.3%) had at least one HIV SDRM; 7 (2.5%, 95% CI 1.0% -5.0%) had NRTI SDRMs; 8 (2.8%, 95% CI 1.2% -5.5%) had NNRTI SDRMs; and 6 (2.1%, 95% CI 0.8% -4.5%) had PI SDRMs (Table S1 ). In 2008, 2009 and 2010, a total of 5/124 (4.0%), 5/84 (6.0%) and 4/76 Transmitted HIV drug resistance for three consecutive years in Bangkok (5.3%) subjects had any SDRM, respectively ( Table 2 ). The most prevalent mutations were NRTI-associated T215D/F/I/Y (1.8%) and M184V/I (1.4%), NNRTI-associated K103N (1.1%) and Y181C (1.8%) and PI-associated V82A (1.1%) ( Table S1 ).
The frequency of TDR to NRTIs and NNRTIs, but not to PIs, showed an increasing trend from 2008 to 2010 (P ¼ 0.07; Table 2 
Mutation scoring per year by drug class
Only efavirenz showed significant differential predicted resistance over the years (P,0.01; Figure S1 Figure S1 ). No significant changes in predicted PI resistance (lopinavir/ritonavir and atazanavir/ritonavir) by year were seen.
Comparison of TDR prevalence with WHO-recommended methods
The WHO surveillance threshold method to estimate TDR prevalence by drug class (NRTI, NNRTI, PI and any) and year performed well using our data (Table S2 ) and corresponded to 10 of our 12 estimates (Table S2 ). The two discordances were: (i) any TDR in 2008, 4% (low) by our data and intermediate (5%-15%) by WHO algorithm; and (ii) NRTI TDR in 2009, 2.4% (low) by our data and intermediate by WHO algorithm. In each case, our calculated 95% confidence intervals overlapped with the WHO algorithm.
Discussion
Our study highlights the changes in TDR in an MSM-predominant population over three consecutive years in a resource-limited setting. Of the 284 analysable RT/Pr sequences from the 299 subjects enrolled from 2008 to 2010, 14 (4.9%) had at least one SDRM, distributed almost equally among the three drug classes (NRTI, NNRTI and PI). TDR to NRTIs and NNRTIs, but not to PIs, showed an increasing trend from low prevalence in 2008 to intermediate prevalence in 2010 (P ¼ 0.07). Only rilpivirine had greater predicted resistance with time. Good, though not complete, correlation was found between our results and the WHO methods.
Temporal changes in TDR have been inconsistent in different parts of the world. Initially, high TDR prevalence (6.2% -21%) was reported in Western countries, 8 -10 which then stabilized or declined. A review of time trends of TDR prevalence by Frentz et al. TDR in this study was associated mainly with zidovudine (T215D/F/I/Y), lamivudine (M184V/I) and NNRTIs (K103N and Y181C). These are the drugs and drug classes that have been used in first-line regimens since the start of universal access to ART in Thailand in 2004. 12 These findings and the observed trends in the study years warrant evaluation of resistance to the new NNRTIs before their use in subsequent regimens. HIVDR testing prior to ART initiation as used in the developed world 13 is difficult to implement in resource-limited settings due to cost and infrastructure constraints unless cost-effectiveness can be proved. 14 In this study, comparability of the WHO threshold surveillance method of using small sample sizes was compared with results from our larger sample set. Although actual testing from a larger sample size should theoretically be more accurate than estimation from a more limited number, we found that the WHO's costsaving method compared well with the actual testing in most circumstances.
The main limitation of our study is the inclusion of patients from only one HIV testing site in Bangkok, comprised mainly of patients from urban areas and who were self-reported MSM. Additional surveys of different target populations within a range of geographic and demographic settings would be needed to confirm national trends in increasing TDR. However, the data complement other epidemiologic studies of the prevalence and incidence of HIV in Bangkok.
In summary, our results show that the prevalence of TDR may be increasing in Bangkok, Thailand, where the scaling up of ART has been ongoing since 2004. Strategies to prevent treatment failure and secondary transmission of HIV should target those at highest risk of infection and drug resistance. Greater efforts to support the 
